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a b s t r a c t
Objective: The Ministry of Health (MOH), Mongolia, is considering introducing 13-valent pneumococcal
conjugate vaccine (PCV13) in its national immunization programme to prevent the burden of disease
caused by Streptococcus pneumoniae. This study evaluates the cost-effectiveness and budget impact of
introducing PCV13 compared to no PCV vaccination in Mongolia.
Methods: The incremental cost-effectiveness ratio (ICER) of introducing PCV13 compared to no PCV vac-
cination was assessed using an age-stratified static multiple cohort model. The risk of various clinical pre-
sentations of pneumococcal disease (meningitis, pneumonia, non-meningitis non-pneumonia invasive
pneumococcal disease and acute otitis media) at all ages for thirty birth cohorts was assessed. The anal-
ysis considered both health system and societal perspectives. A 3 + 0 vaccine schedule and price of US
$3.30 per dose was assumed for the baseline scenario based on Gavi, the Vaccine Alliance’s advance mar-
ket commitment tail price.
Results: The ICER of PCV13 introduction is estimated at US$52 per disability-adjusted life year (DALY)
averted (health system perspective), and cost-saving (societal perspective). Although indirect effects of
PCV have been well-documented, a conservative scenario that does not consider indirect effects esti-
mated PCV13 introduction to cost US$79 per DALY averted (health system perspective), and US$19 per
DALY averted (societal perspective). Vaccination with PCV13 is expected to cost around US$920,000 in
2016, and thereafter US$820,000 every year. The programme is likely to reduce direct disease-related
costs to MOH by US$440,000 in the first year, increasing to US$510,000 by 2025.
Conclusion: Introducing PCV13 as part of Mongolia’s national programme appears to be highly cost-
effectivewhen compared to no vaccination and cost-saving from a societal perspective at vaccine purchase
prices offered through Gavi. Notwithstanding uncertainties around some parameters, cost-effectiveness of
PCV introduction for Mongolia remains robust over a range of conservative scenarios. Availability of high-
quality national data would improve future economic analyses for vaccine introduction.
 2017 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
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1. Background
Streptococcus pneumoniae caused an estimated 500,000 deaths
worldwide among children under five years of age in 2008 [1]. In
Mongolia, pneumonia is a leading cause of childhood mortality,
as well as accounting for 51% of all-age respiratory disease admis-
sions [2]. Severe air pollution, especially in winter, exacerbates the
problems caused by pneumonia and other acute respiratory infec-
tions [3]. Shortage of equipment, drugs and skilled health profes-
sionals, mostly in rural areas, further contribute to high
preventable mortality from pneumonia [4]. S. pneumoniae and Hae-
mophilus influenzae type b (Hib) are leading causes of childhood
pneumonia-related deaths [5] and cause a substantial portion of
meningitis and sepsis, in the absence of vaccination. Since intro-
duction of Hib vaccine in 2005 in Mongolia [6], the continuing high
rate of childhood pneumonia is attributable to pneumococcus
more than any other single cause.
In accordance with World Health Organization (WHO) recom-
mendations to include pneumococcal conjugate vaccines (PCVs)
in childhood immunization programs worldwide [1], Mongolia
plans to introduce the 13-valent PCV (PCV13) into its Expanded
Programme on Immunisation in a 3 + 0 schedule (three primary
doses at 2, 3 and 4 months of age without a booster dose) that
would coincide with the oral polio and pentavalent vaccine sched-
ules [7]. PCV13 (or Prevnar-13) protects against invasive pneu-
mococcal disease (IPD), pneumonia and acute otitis media (AOM)
from S. pneumoniae.
The pneumococcal Advance Market Commitment (AMC) is an
innovative funding mechanism incentivising vaccine makers to
produce affordable vaccines for the world’s poorest countries. Min-
istry of Health (MOH), Mongolia applied to Gavi, the Vaccine Alli-
ance (Gavi) in 2013 to purchase PCV13 through the AMC
mechanism and received Gavi approval in March 2014 for PCV
introduction starting in 2016, with the intent of scaling up to a
nationwide programme. Although Mongolia’s current Gross
National Income (GNI) per capita is above Gavi’s threshold and
the country is therefore transitioned out of Gavi support in 2016,
it remains eligible for PCV vaccine prices under the AMC even after
being fully self-financed [8]. However, introduction of PCV will still
require financing to cover costs of vaccine purchase and vaccina-
tion within the immunization programme. Mongolia’s government
has thus identified the need to assess the cost-effectiveness and
financial sustainability of PCV13 introduction in the Mongolian
context [7].
A collaboration between MOH, local and foreign investigators
was established to conduct an economic evaluation for PCV intro-
duction to inform decision making and establish the case for sus-
tained investment. This evaluation is the first country-specific
study to assess the costs and outcomes associated with PCV13, in
order to determine whether PCV13 is cost-effective to introduce
as part of Mongolia’s national immunisation programme, as well
as its likely budget impact.
2. Methods
2.1. Model overview and analytic framework
In order to investigate the value for money and financial
sustainability respectively of vaccination the incremental
cost-effectiveness of introducing PCV13 compared to no PCV vacci-
nation was assessed using an age-stratified static multiple-cohort
model (Fig. 1). The model assesses the risk of various clinical
presentations of pneumococcal disease—meningitis (including
sequelae), pneumonia, non-pneumonia non-meningitis (NPNM)
IPD and AOM)—for each year of life between 0 and 100, in both
vaccinated and unvaccinated individuals, and both with and with-
out a vaccination programme. Each disease episode is associated
with a cost and health utility loss. Thirty consecutive birth cohorts
were assessed over a thirty year time period. The direct effect of
PCV (direct population effects) is assessed by a proportionate
reduction in pneumococcal disease risk in vaccinated individuals.
The indirect effects of PCV introduction—herd protection (referring
to a lower risk of infection among unvaccinated individuals due to
increase in population-level immunity, generated by reduction in
carriage of vaccine serotypes) and serotype replacement (a phe-
nomenon referring to an increase in incidence of invasive disease
caused by non-vaccine serotypes and proportion of carriage of
non-vaccine serotypes after vaccine introduction)—are also consid-
ered by an adjustment to disease risk in unvaccinated individuals
in the presence of a population-wide vaccination programme.
Although there is substantial evidence for the existence of these
indirect effects from post-introduction surveillance [9,10], the
magnitude of such effects is uncertain, so we considered an alter-
native conservative scenario without indirect effects.
The budget impact analysis was conducted over a 10 year hori-
zon. For each year of the analysis, costs were calculated from net
costs from all modelled birth cohorts (including adult cohorts
affected by indirect vaccine effects) that were born in the same
or previous years. All direct costs were assumed to be included
in the budget impact; indirect societal costs were also shown in
a sensitivity analysis.
Costs were inflated to 2014 prices based on Mongolia’s inflation
rate of 15.0% in 2012 and 8.6% in 2013 [11]. Costs were then con-
verted into United States (US) dollars using the average exchange
rate for the year 2014 between the US dollar (US$) and the Mongo-
lian tugrik (MNT): 1 US$ = 1804.50 MNT. Future costs and out-
comes were discounted from the first year of vaccination at 3%
per annum [12]. The analysis was done from the perspective of
both the health system and society. Health system costs included
vaccine costs (purchase, freight and administration), cold chain,
surveillance, and hospitalization or health centre consultation
costs. Societal costs considered productivity losses and out-of-
pocket expenses in addition to health system costs noted above.
Table 1 shows base case parameters used in the model.
2.2. Demographics
Population estimates for 2012 stratified by year of age were
obtained in hard copy from the National Statistical Office, Mongo-
lia and life expectancies were obtained from WHO’s 2011 Life
Tables for Mongolia [13].
2.3. Vaccine coverage
A 3 + 0 schedule with vaccine coverage of 98.2% and 97.6% for
first and third dose, respectively, was assumed, based on adminis-
trative coverage data of diphtheria-tetanus-pertussis vaccine given
at the same ages [14]. Second dose coverage was assumed to be the
average of the first and third doses. In addition, buffer stock of 25%
of first dose coverage and 2% wastage (based on wastage for pen-
tavalent vaccine communicated through the Expanded Programme
on Immunization) was assumed.
2.4. Vaccine cost
A per-dose cost of $3.30 was used, since Mongolia is eligible to
purchase pneumococcal vaccines at the Gavi AMC ‘tail price’ [8] set
at $3.30 from 2014 onwards based on the third AMC supply agree-
ment (22 July 2013) [15]. An additional 4% was added to account
for vaccine freight as well as $0.0605 and $0.008 per dose for
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syringe and safety box purchase, respectively [16]. Customs and
handling costs at 19% were included [16]. The cost of 5 min of a
nurse’s time $229.27/month (413,720 MNT/month) based on a
nurse’s average salary was further assumed.
Cold chain costs included purchases of refrigerators (at approx-
imately $1000 per unit) to store vaccine doses at the central level
and in the provinces based on a quarterly procurement of PCV13
[17]. Surveillance for pneumococcal disease has already been
established in Mongolia, so only incremental annual maintenance
costs of $100,738 were included to cover costs for centralized spec-
imen testing and data management, based on past WHO-funded
surveillance activities.
2.5. Vaccine efficacy
Efficacy of 9-valent PCV with a 3 + 0 schedule in HIV negative
patients from a South African trial (83%) [18] was used as HIV
prevalence in Mongolia is very low [19]. Efficacy data from a study
in Gambia were not used as they were not stratified by HIV status
[20]. However, PCV13 has shown poor efficacy against IPD associ-
ated with serotype 3, ranging from 68% in the USA [21] to non-
significant in England [22]. Hence, an overall efficacy of 34%
against serotype 3 IPD was assumed. We also assumed that
1.03% of vaccine type IPD was caused by serotype 3 based on esti-
mates for Asia [23]. Efficacy against vaccine type IPD was thus
scaled down to 82.5%. Vaccine efficacy of 20.2% against all-cause
AOM was assumed [24], by scaling up PCV10 vaccine efficacy of
19% in the most recent trial (COMPAS) [24] to include the contribu-
tion of PCV13 against serotypes 6A and 19A. Average vaccine dura-
tion of protection of 8.3 years was assumed as with previous
modelling work [25]. It was conservatively assumed that three
doses were required for protection.
Distribution of serotypes was based on the Pneumococcal Glo-
bal Serotype Project, where proportion of IPD due to each serotype
for Asia were used (73.7%) [23]. No reliable carriage data for Mon-
golia were available, so we instead used data from a study of
nasopharyngeal swabs of children visiting outpatient clinics in
Kazakhstan, Uzbekistan and Kyrgyz Republic [26].
2.6. Disease burden
Incidence and case-fatality risks (CFRs) for pneumococcal
meningitis, NPNM IPD and pneumonia was obtained from WHO
estimates for Mongolia [27]. These are summarised in Table 1;
details of their estimation are in Supplementary material. Mongo-
lia estimates were scaled by data from Philippines [28] and rural
Thailand [29] for age-specific incidences. All-cause AOM incidence
was obtained from a systematic review of published studies [30].
2.7. Hospitalization and health centre visit costs, out-of-pocket costs
and productivity losses
Hospitalization costs were obtained from sources in Mongolia
and are summarised in Table 1 with details in Supplementary
material. Similarly for parameters of medical care-seeking for chil-
dren with pneumonia and AOM [31,32].
To calculate productivity losses for caregivers of children under
18 years old, the average hospital stay or health centre visit was
multiplied by the female labour force participation rate (58.4%)
[33]. Each day of work lost was valued at Mongolia’s gross domes-
tic product (GDP) per capita [34]. Out-of-pocket (OOP) expendi-
tures were estimated using the WHO global health expenditure
database [35] and a local pneumonia costing study. They included
expenses for travel, additional drugs and tests and miscellaneous
expenses as determined through patient surveys. They are sum-
marised in Table 1 with details in Supplementary material.
2.8. Disability weights
Disability-adjusted life years (DALYs) lost due to non-fatal
pneumococcal meningitis, pneumonia, NPNM IPD and AOM were
obtained from the Global Burden of Disease [36] and the risk of dif-
ferent kinds of major sequelae of pneumococcal meningitis was
obtained from a global meta-analysis [37], adjusted for WHOWes-
tern Pacific region (WPR). Further details of their estimation are in
Supplementary material.
Fig. 1. Decision tree for a single year of age, depicting two alternative strategies: vaccination with PCV-13 versus no vaccination. An age-stratified decision tree economic
model to represent disease outcomes and associated health states for vaccinated and unvaccinated populations. The same structure is repeated for every year of age between
0 and 100 years. The ‘no vaccination’ node has the same branches as the vaccination node.
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2.9. Indirect effects
Indirect effects were extrapolated from IPD incidence following
PCV13 introduction in the United Kingdom (UK) between 2010/11
and 2013/14 [38]. Based on UK observed data, age-dependent inci-
dence prior to PCV7 introduction (2005/2006) was used as a base-
line and proportional decrease in yearly age-dependent incidence
from 2010 to 2014 were calculated. This proportional decline
Table 1
Base case parameters used in the model.
Parameter Value Source
Vaccine characteristics
Efficacy
. . . against vaccine-type IPD 82.5% Klugman 2003 [18] Kaplan 2013 [21] and Andrews 2014 [22]
. . . against vaccine-type pneumococcal carriage 82.5% Assumed same as vaccine-type IPD
. . . against all-cause acute otitis media (PCV13) 20.2% Tregnaghi 2014 [24]
Coverage (in targeted population)
. . . dose one 98.2% Ministry of Health, Mongolia. WHO/UNICEF Joint Reporting Form on Immunization, data for 2013 [14]
. . . dose two 97.9% Estimated as average of first and third doses
. . . dose three 97.6% Ministry of Health, Mongolia. WHO/UNICEF Joint Reporting Form on Immunization, data for 2013 [14]
Costs (US$2014)
Vaccination
. . . purchase (PCV13) $3.30 Gavi, the Vaccine Alliance [15]
. . . freight (PCV13) $0.14 UNICEF Supply Division, Immunization forecast overview, Recommended budget prices for 2014 [16]
. . . buffer stock 25% Assumption
Hospitalization
. . . meningitis $271.0 Health Insurance Fund, Mongolia
. . . pneumonia $160.3 Pneumonia costing study 2012, Mongolia
. . . invasive NPNM $271.0 Same as for meningitis
Health centre consultation
. . . acute otitis media $8.3 Decree by Ministry of Health and Social Health Insurance Office, Mongolia in 2014
Productivity costs
. . .female labour force participation rate 58.4% National Statistical Office of Mongolia, Ulaanbaatar 2013 [33]
. . .Gross domestic product per capita in 2014 $4056.4 World Bank, 2014. World Development Indicators. [34]
. . .Meningitis average hospital stay 10 days 2012 hospital records matched by ICD-10 codes from National Center for Health Development, Mongolia
. . .Sepsis (proxy for NPNM) average hospital stay 9 days
. . .Pneumonia average hospital stay 7 days
. . .Days of work lost from acute otitis media 1 day Assumption
Out of pocket (OOP) costs
. . . meningitis $145.9 OOP as percentage of total health care expenditure [35]
. . . pneumonia $86.3 Pneumonia costing study 2012, Mongolia
. . . invasive NPNM $145.9 OOP as percentage of total health care expenditure [35]
. . . acute otitis media $4.5 OOP as percentage of total health care expenditure [35]
Proportion of patients who seek care
. . . Acute otitis media (health care centre) 48% Kazakhstan DHS,1999 [32]
. . . Non-invasive pneumonia 87% National Statistics Office, UNICEF. MICS 2010 Summary Report [31]
Disease burden
Incidence (per 100,000)
. . .meningitis 11 WHO estimate [27], scaled by age-specific incidence from Capeding 2013 [28]
. . .invasive NPNM 62
. . .pneumonia 1345 WHO estimate [27], scaled by age-specific incidence from Hasan 2014 [29]
Case-fatality risk
. . .meningitis 34.6% WHO estimate for Mongolia [27]
. . .invasive NPNM 27.1% WHO estimate for Mongolia [27]
. . .pneumonia 5.4% WHO estimate for Mongolia [27]
Disability weights
. . . Meningitis (per episode) 0.62 ‘‘Meningitis, S. pneumoniae” in Mathers 2006 [36]
. . . Pneumonia (per episode) 0.28 ‘‘Neonatal pneumonia” in Mathers 2006 [36]
. . . NPNM (per episode) 0.15 ‘‘Meningococcaemia without meningitis” in Mathers 2006 [36]
. . . Otitis media (per episode) 0.02 ‘‘Otitis media” in Mathers 2006 [36]
. . . Major cognitive difficulties (per year) 0.46 ‘‘Mental retardation” in Mathers 2006 [36]
. . . Major seizure disorder (per year) 0.10 ‘‘Seizure” in Mathers 2006 [36]
. . . Major hearing loss (per year) 0.12 ‘‘Deafness” in Mathers 2006 [36]
. . . Major motor deficit (per year) 0.38 ‘‘Motor deficit” in Mathers 2006 [36]
. . . Major visual disturbance (per year) 0.60 ‘‘Blindness” in Mathers 2006 [36]
. . . Major clinical impairment (per year) 0.10 ‘‘Seizure” in Mathers 2006 [36]
Pneumococcal meningitis sequelae risk
. . . Major cognitive difficulties 3.6% Edmond [37]
. . . Major seizure disorder 3.0% Edmond [37]
. . . Major hearing loss (per year) 8.0% Edmond [37]
. . . Major motor deficit (per year) 3.9% Edmond [37]
. . . Major visual disturbance (per year) 1.4% Edmond [37]
. . . Major clinical impairment (per year) 4.0% Edmond [37]
Costs were standardized for 2014 prices, and where necessary, inflated to 2014 prices based on Mongolia’s inflation rate of 15% in 2012 and 8.6% in 2013. IPD: invasive
pneumococcal disease; nIPD: non-invasive pneumococcal disease; NPNM: non-pneumonia non-meningitis.
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was applied to Mongolian incidence in the first four years of PCV
introduction and we assumed constant proportion thereafter.
Post-introduction surveillance in other countries [9,39] show the
same qualitative trends, but UK data was used because it tracks
the year-on-year change from baseline. Changes in incidence of
vaccine-type and non-vaccine type IPD compared to the last year
before vaccine introduction (2006/7) were used as indications of
herd protection and serotype replacement, respectively. The direct
effect of vaccination on vaccine-type disease was estimated as the
product of vaccine efficacy for a 2 + 1 schedule in a high-income
context (95%) [25] and coverage (95%) in vaccinated age groups.
It was assumed that in the first year effective vaccine coverage is
halved due to the time it takes to vaccinate an entire age cohort.
The proportionate decrease in vaccine-type IPD and increase in
non-vaccine type IPD was then applied to Mongolia, after adjusting
proportionally for differences in vaccine coverage, serotype distri-
bution and efficacy of the 3 + 0 schedule in a middle-income
context. In the base case, given 97.6% coverage for 3 doses, 73.7%
serotype coverage and 82.5% vaccine efficacy, indirect effects were
assumed to be 88.6% of that in the UK.
2.10. Sensitivity analyses
To explore the robustness of conclusions to assumptions, the
following sensitivity scenarios were modelled by varying costs
and disease burden (Table 2):
i. Vaccine cost: Scenarios with higher vaccine purchase cost (a)
Gavi AMC maximum tail price of $3.50 [8] and (b) the higher
Pan American Health Organization (PAHO) Revolving Fund
price of $15.68 [40]
ii. Hospitalization cost: As an upper limit for potential hospital-
ization costs, in the event of escalating costs, we include a
scenario using outputs from WHO-CHOICE to estimate
Table 2
Parameters for various sensitivity scenarios and base case.
Base case S1: Max Gavi tail $ S2: PAHO $ S3: WHO-CHOICE S4: Low incid & CFR S5: High incid & CFR
Cost
Vaccine cost $3.30 $3.50 $15.68 $3.30 $3.30 $3.30
Hospitalization cost
Meningitis $271.02 $271.02 $271.02 $1,771.44 $271.02 $271.02
Pneumonia $160.30 $160.30 $160.30 $527.63 $160.30 $160.30
NPNM $271.02 $271.02 $271.02 $1,771.44 $271.02 $271.02
Out-of-pocket cost
Meningitis $145.93 $145.93 $145.93 $953.85 $145.93 $145.93
Pneumonia $86.32 $86.32 $86.32 $284.11 $86.32 $86.32
NPNM $145.93 $145.93 $145.93 $953.85 $145.93 $145.93
AOM $4.48 $4.48 $4.48 $5 $4.48 $4.48
Incidence
Meningitis
0 year old 0.00060 0.00060 0.00060 0.00060 0.00003 0.00014
1 year old 0.00018 0.00018 0.00018 0.00018 0.00003 0.00014
2 year old 0.00004 0.00004 0.00004 0.00004 0.00003 0.00014
3 year old 0.00003 0.00003 0.00003 0.00003 0.00003 0.00014
4 year old 0.00006 0.00006 0.00006 0.00006 0.00003 0.00014
Pneumonia IPD
0 year old 0.00063 0.00063 0.00063 0.00063 0.00065 0.00103
1 year old 0.00035 0.00035 0.00035 0.00035 0.00036 0.00058
2 year old 0.00035 0.00035 0.00035 0.00035 0.00036 0.00058
3 year old 0.00035 0.00035 0.00035 0.00035 0.00036 0.00058
4 year old 0.00035 0.00035 0.00035 0.00035 0.00036 0.00058
NPNM
0 year old 0.00228 0.00228 0.00228 0.00228 0.00017 0.00084
1 year old 0.00178 0.00178 0.00178 0.00178 0.00017 0.00084
2 year old 0.00052 0.00052 0.00052 0.00052 0.00017 0.00084
3 year old 0.00012 0.00012 0.00012 0.00012 0.00017 0.00084
4 year old 0.00024 0.00024 0.00024 0.00024 0.00017 0.00084
Pneumonia nIPD
0 year old 0.02038 0.02038 0.02038 0.02038 0.02092 0.03345
1 year old 0.01135 0.01135 0.01135 0.01135 0.01165 0.01863
2 year old 0.01135 0.01135 0.01135 0.01135 0.01165 0.01863
3 year old 0.01135 0.01135 0.01135 0.01135 0.01165 0.01863
4 year old 0.01135 0.01135 0.01135 0.01135 0.01165 0.01863
Case fatality risk
Meningitis U5 0.346 0.346 0.346 0.346 0.100 0.680
Pneumonia IPD U5 0.054 0.054 0.054 0.054 0.010 0.030
NPNM U5 0.271 0.271 0.271 0.271 0.080 0.530
S: scenario; CFR: case fatality risk; Incid: Incidence; U5: children under 5 years old; NPNM: non-pneumonia non-meningitis; IPD: invasive pneumococcal disease; nIPD: non-
invasive pneumococcal disease.
S1: Higher vaccine cost-Gavi AMCmaximum tail price; S2: Higher vaccine cost- Pan American Health Organization Revolving Fund price; S3:Higher hospitalization costs from
WHO-CHOICE; S4: Minimum-impact scenario for vaccine introduction, using lower bounds from regional estimates for incidence and CFR for meningitis, pneumonia and
NPNM IPD; S5: maximum-impact scenario from vaccine introduction, using upper bounds from regional estimates for incidence and CFR for meningitis, pneumonia and
NPNM IPD.
All parameters of the base case and parameters in each of the scenarios where they differ from the base case have been highlighted in bold characters.
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hospitalization cost for pneumococcal meningitis, pneumo-
nia or NPNM IPD. In a univariate linear regression model
using the sample of available countries, GNI per capita sig-
nificantly predicted average treatment cost for meningitis
and pneumonia [41], with a reasonable model fit (R2 of
83% for meningitis and 72% for pneumonia). Applying the
regression estimates to 2013 GNI per capita for Mongolia
($3,770) [42], we estimated the average annual costs per
hospitalized case for meningitis and pneumonia to be
$1,771 and $528. NPNM IPD treatment cost was assumed
to be the same as for meningitis. Out-of-pocket expenditures
were calculated as before using a factor of 35% of Total
Health Expenditure [35].
iii. Disease burden: A minimum-impact scenario for vaccine
introduction with low disease rates and CFR, using lower
bounds from WPR estimates, and conversely a maximum-
impact scenario using upper bounds from WPR estimates
were considered [43]. Regional lower and upper bound esti-
mates per 100,000 were: pneumonia: 1381–2208; meningi-
tis: 3–14; and NPNM IPD: 17–84 [43]. In all cases, incidence
in the base case scenario was similar to the regional estimate
or its lower bound. Lower and upper bounds for regional CFR
estimates were: meningitis: 10–68%, pneumonia: 1–3% and
severe NPNM IPD: 8–53% [43].
3. Results
3.1. Base case
The incremental cost-effectiveness ratio (ICER) per DALY
averted from PCV13 introduction in Mongolia is estimated to be
$52 from a health system perspective, and cost-saving from a soci-
etal perspective (Table 3). In an alternative conservative scenario
that considers population direct effects only without herd effects
due to reduced transmission (although herd effects of pneumococ-
cal conjugate vaccines have been well-documented), introducing
PCV13 is estimated to cost $79 from a health system perspective,
and $19 from a societal perspective (Table 3).
3.2. Sensitivity analyses
Table 4 shows how the cost per DALY averted from PCV13 vac-
cination may change for the scenarios considered in the sensitivity
analyses. The most pessimistic scenario was purchase of PCV13 at
the higher PAHO price, which cost $460 and $390 per DALY averted
from health system and societal perspectives, respectively ($540
and $480, respectively, when considering the unlikely but further
conservative case of population direct effects only from vaccine).
The minimum impact scenario that considered the conservative
lower bounds of disease incidence and CFRs, cost $110 per DALY
averted from a health system perspective and was cost-saving
from a societal perspective. Additional, one-way sensitivity analy-
ses varying vaccine-related parameters, disease burden and dis-
ability weights by ±25% also showed PCV13 vaccination to be
cost-effective (Tornado diagram, see Supplementary figure).
3.3. Budget impact
Fig. 2 displays the impact that vaccination with PCV13 may
have on the health care budget for MOH, as well as on wider soci-
etal costs, in 2014 US$ (i.e., not considering inflation). A constant
birth cohort size and no vaccine price maturation were assumed.
Vaccination with PCV13 is expected to cost around $920,000 in
the first year assuming increase in cold chain capacity, and there-
after cost around $820,000 every year. The vaccination programme
is likely to reduce direct costs to the health care budget by about
$440,000 in the first year, increasing to $510,000 by 2025. Societal
costs, which includes productivity losses and out-of-pocket
expenses, are also likely to be reduced by about $380,000 in
2016, rising to $480,000 by 2025.
Table 3
Incremental outcomes of PCV13 compared to no vaccination over thirty years.
Direct and indirect population effects
(base case)a
Direct population effects onlyb
No vaccination
with PCV
Vaccination
with PCV13
Difference: Vaccination
with PCV13 vs. no
PCV vaccination
Vaccination
with PCV13
Difference: Vaccination
with PCV13 vs. no
PCV vaccination
Number of children vaccinated with 3 doses 0 1.9 mil 1.9 mil 1.9 mil 1.9 mil
Total vaccination cost (undiscounted) $0 $19 mil $19 mil $19 mil $19 mil
Freight, administration cost (undiscounted) $0 $5.6 mil $5.6 mil $5.6 mil $5.6 mil
Health care costs (undiscounted) $51.7 mil $36.6 mil $15.1 mil $40.0 mil $11.8 mil
Societal costs (undiscounted) $54.6 mil $40.5 mil $14.2 mil $44.3 mil $10.4 mil
IPD cases 17,700 10,800 6,890 10,040 7,700
Non-IPD pneumonia cases 217,000 132,000 85,200 158,000 58,900
Acute otitis media cases 4,360,000 3,940,000 417,000 3,940,000 417,000
Deaths 15,200 9,240 5,950 10,300 4,900
DALYs lost (undiscounted) 548,000 364,000 184,000 378,000 170,000
DALYs lost (discounted) 358,000 237,000 121,000 250,000 108,000
Total costs with productivity (undiscounted) $106 mil $102 mil $4.72 mil $109 mil $2.44 mil
Total costs with productivity (discounted) $ 69.5 mil $66.5 mil $2.96 mil $71.5 mil $2.02 mil
Total costs without productivity (undiscounted) $51.7 mil $61.2 mil $9.46 mil $64.5 mil $12.8 mil
Total costs without productivity (discounted) $33.8 mil $40.0 mil $6.25 mil $42.4 mil $8.62 mil
Incremental cost-effectiveness ratio (with productivity) Cost saving $19
Incremental cost-effectiveness ratio (without productivity) $52 $79
Mil: million; Incremental cost-effectiveness ratio: Cost per DALY averted; IPD: Invasive pneumococcal disease.
In this analysis, following World Health Organization recommendations [14], future costs and health outcomes were both discounted to their present values (in the year
2014) at a rate of 3% per annum. Discounting allows for comparison of costs and benefits across different time periods, by weighting future gains and losses less heavily than
those in the present to account for time value.
Both health system (excluding productivity losses) and societal (considering productivity losses and out-of-pocket expenses) perspectives are shown.
Figures are reported to two or three significant figures for visual clarity. Some apparent discrepancies may result due to this rounding.
a Base case model assuming serotype replacement and herd protection (both direct and indirect effects of vaccine).
b An alternate conservative model considering direct effects of vaccine alone (no serotype replacement and no herd protection).
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4. Discussion
The ICER for PCV13 introduction in Mongolia—$52 per DALY
averted and cost-saving from health care provider and societal per-
spectives, respectively—is substantially lower than Mongolia’s GDP
per capita ($4,056.40 in 2013) sometimes used as a threshold for
cost-effectiveness [34], as well as a much lower threshold of
$122–$173 suggested by the University of York based on the mor-
tality effects of health expenditure [44]. It also compares favour-
ably to previously estimated ICERs of $114–$123 per DALY for
rotavirus vaccination [45] and $470 per DALY for HPV vaccination
at Gavi prices [46]; and $91–$110 per DALY from a regional analy-
sis for Hib vaccine [41]. Hence PCV13 introduction is likely to be a
cost-effective decision for Mongolia. The ICER of PCV13 introduc-
tion remains well below GDP per capita (and usually below the
other thresholds examined) across the range of potential scenarios
considered.
Our study is the first country-specific PCV cost-effectiveness
evaluation in Mongolia, but is consistent with more general analy-
ses. For example, one study concluded that using PCV in the 72
Gavi-eligible countries in 2005 would have an ICER of about
$100 per DALY prevented; this analysis used the societal perspec-
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Fig. 2. Budget impact of PCV13 vaccination in Mongolia over 2016–2025. Undiscounted vaccination costs (at $3.3 per dose based on purchase price for Ministry of Health,
Mongolia through Gavi, the Vaccine Alliance’s AMC tail price) and costs saved from both a health system perspective as well as societal perspective are displayed.
Table 4
Incremental cost-effectiveness ratios per DALY averted from PCV13 introduction in alternative scenarios to the base case.
Direct & indirect population effects
PCV13 (with serotype replacement and herd protection) vs. no PCV
Societal perspective Health system perspective
Base case
Base case Cost-saving $52
Cost
Scenario 1: Vaccine cost using maximum AMC tail price (US$3.50) Cost-saving $58
Scenario 2: Vaccine cost using PAHO price (US$15.68) $390 $460
Scenario 3: Hospitalization cost using WHO-CHOICE Cost-saving $17
Incidence & case fatality risk (Meningitis, Pneumonia, NPNM IPD)
Scenario 4: Lower bound from regional estimates for Western Pacific [43] Cost-saving $180
Scenario 5: Upper bound from regional estimates for Western Pacific [43] Cost-saving $10
Direct population effects only
PCV13 (no serotype replacement, no herd protection) vs. no PCV
Societal perspective Health system perspective
Base case
Base case $19 $79
Cost
Scenario 1: Vaccine cost using maximum AMC tail price (US$3.50) $26 $87
Scenario 2: Vaccine cost using PAHO price (US$15.68) $480 $540
Scenario 3: Hospitalization cost using WHO-CHOICE Cost-saving $27
Incidence & case fatality risk (Meningitis, Pneumonia, NPNM IPD)
Scenario 4: Lower bound from regional estimates for Western Pacific [43] $110 $312
Scenario 5: Upper bound from regional estimates for Western Pacific [43] Cost-saving $46
Figures are reported to two significant figures for visual clarity.
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tive and considered direct population effects only [47]. The corre-
sponding ICER from our analysis for Mongolia was $19. While care
should be taken in comparing results from economic models, this
suggests that PCV13 is indeed highly cost-effective for Mongolia.
The price at which PCV13 is being offered through Gavi is a
major factor in making PCV13 highly cost-effective or cost-saving
for introduction in Mongolia. Although the price is low relative
to prices offered for PCV13 globally, the total vaccine cost to the
country still amounts to $920,000 in the first year due to additional
cold chain capacity costs for PCV and $820,000 per year in subse-
quent years for national introduction. Furthermore, even at the
higher PAHO revolving fund price, which we do not reasonably
expect Mongolia’s vaccine purchase price to exceed even after
transition out of Gavi’s AMC price, PCV13 introduction was highly
cost-effective. In addition to vaccine cost, disease incidence was a
major driver influencing the cost-effectiveness analysis. However,
even at lower bounds of incidence and case fatality risk, introduc-
tion of PCV13 was cost-effective for Mongolia.
Mongolian public expenditure on health in 2014 is 2.6% of GDP,
which is around three hundred million dollars. As seen from the
budget impact analysis, total yearly PCV13 vaccine costs to the
country represents approximately 0.3% of the annual public spend-
ing on health. While this is not trivial sum, a decreased pneumo-
coccal disease burden from PCV vaccination is estimated to
reduce disease-related spending by $500,000. Furthermore, when
economic costs to the wider society are considered, additional sav-
ings of $400,000 per year results in an annual potential budget sav-
ing of around $100,000 to $200,000.
A limitation of this analysis was an absence of local data for age-
specific disease burden, as is common in many low and middle
income countries with limited resources for bacteriological
surveillance. Data from the Philippines and Thailand was thus
extrapolated based on inter-country similarities in terms of GNI
per capita, life expectancy, proportion of deaths from and health-
seeking for respiratory infections, etc. (see Supplementary mate-
rial. Country profiles). Availability of local data would enhance
the representativeness of this analysis. However, our results are
robust to varying the parameters extrapolated from other settings
within large ranges representing the range of values of countries in
the WPR. Hence our analysis suggests ways that useful conclusions
can be drawn from economic evaluations in countries with limited
epidemiological data. More local data would also allow us to con-
duct probabilistic sensitivity analyses to assess uncertainty of all
parameters together.
Finally, some assumptions were made regarding the health sys-
tem’s capacity for effective delivery of this additional vaccine
including necessary investments to maintain the quality of surveil-
lance for adverse events following immunization, supply distribu-
tion systems and monitoring. Furthermore, other healthcare costs,
such as training, social mobilization and surveillance capacity
building prior to vaccine introduction were not included. Our
model therefore underestimates the administrative costs of vac-
cine introduction. However, these costs are expected to be small
relative to the costs of vaccine and related supplies.
Recently, MOH and WHO in Mongolia have discussed using a 2
+ 1 vaccine schedule instead of the originally planned 3 + 0 sched-
ule [7], which this analysis is based on. Since, number of vaccine
doses remains unchanged and no significant differences in impact
on disease burden between schedules have been currently
established [48,49], we do not expect the conclusions to change
for a 2 + 1 schedule.
In conclusion, routine infant vaccination against S. pneumoniae
with PCV13 appears to be highly cost-effective when compared
to no vaccination in Mongolia. Continued investment in this vacci-
nation programme is likely to be the right economic decision
despite the present financial challenges in Mongolia.
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